ELACESTRANT HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H38N2O2.2ClH
Molecular Weight	531.557
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.[H][C@]1(CCC2=CC(O)=CC=C2C1)C3=C(C=C(OC)C=C3)N(CC)CC4=CC=C(CCNCC)C=C4

InChI

InChIKey=XGFHYCAZOCBCRQ-FBHGDYMESA-N

InChI=1S/C30H38N2O2.2ClH/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26;;/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3;2*1H/t26-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C30H38N2O2
Molecular Weight	458.6349
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28473534 | https://radiuspharm.com/pipeline/ | https://adisinsight.springer.com/drugs/800027755

Elacestrant (ER-306323 or RAD 1901 [6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride]) is a selective estrogen receptor (ER) degrader. Elacestrant induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth in breast cancer xenograft models. Elacestrant has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Elacestrant is being developed by Radius Health, for the treatment of estrogen receptor positive breast cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 75 Target ID: P03372 Gene ID: 2099.0 Gene Symbol: ESR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26162914 \| https://www.ncbi.nlm.nih.gov/pubmed/27575546	Modulator 828

PubMed

Title	Date	PubMed
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER(+) Breast Cancer Patient-derived Xenograft Models.	2017 Aug 15	28473534

Sample Use Guides

In Vivo Use Guide

400 mg/day once daily

Route of Administration: Oral

In Vitro Use Guide

Elacestrant treatment also inhibited E2-mediated proliferation in MCF7 and T47D cells in a dose-dependent manner

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:42:51 GMT 2023` Edited by `admin` on `Sat Dec 16 09:42:51 GMT 2023`
Record UNII	8NZT0PR8AL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ELACESTRANT HYDROCHLORIDE

Official Name

English

ELACESTRANT DIHYDROCHLORIDE

Preferred Name

English

RAD1901 DIHYDROCHLORIDE

Code

English

ORSERDU

Brand Name

English

2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, hydrochloride (1:2), (6R)-

Systematic Name

English

(6R)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol hydrochloride (1:2)

Systematic Name

English

ELACESTRANT HYDROCHLORIDE [USAN]

Common Name

English

RAD-1901 DIHYDROCHLORIDE

Code

English

Code System Code Type Description

NCI_THESAURUS

C171898